A covalent inhibitor targeting Cys16 on RhoA in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RhoA is a critical regulator of cell functions and a known driver in colorectal cancer (CRC) development.
• Despite its importance, RhoA remains an undrugged target in clinical settings.
• Targeting RhoA presents a promising avenue for novel CRC therapies.

Purpose of the Study:

• To identify and characterize novel inhibitors targeting RhoA for colorectal cancer treatment.
• To evaluate the efficacy and safety of a newly developed RhoA inhibitor, CL16, in preclinical CRC models.
• To explore the therapeutic potential of targeting the unique Cys16 residue on RhoA.

Main Methods:

• Activity-based protein profiling (ABPP) coupled with mass spectrometry (MS) to discover RhoA inhibitors.
• In vitro assays to assess the inhibitory activity of CL16 on RhoA and its downstream effects.
• In vivo studies using mouse models of colorectal cancer to evaluate antitumor and antimetastatic efficacy, as well as toxicity.

Main Results:

• CL16 identified as a specific covalent inhibitor targeting Cys16 on RhoA subfamily.
• CL16 effectively inhibits RhoA activity in CRC cells, leading to cell-cycle arrest, apoptosis, and cancer cell death.
• CL16 demonstrated significant antitumor and antimetastatic effects in mouse CRC models with no observable toxicity.
• CL16 treatment promoted T cell infiltration within the tumor microenvironment.

Conclusions:

• Covalent targeting of the druggable Cys16 residue on RhoA is a viable and specific strategy for CRC therapy.
• CL16 shows promise as a potential therapeutic agent for colorectal cancer, warranting further clinical development.
• The findings provide a strong foundation for the development of targeted RhoA inhibitors for cancer treatment.